ID   MTOR_RAT                Reviewed;        2549 AA.
AC   P42346;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-OCT-2024, entry version 207.
DE   RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:9465032};
DE   AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1;
DE   AltName: Full=FKBP12-rapamycin complex-associated protein;
DE   AltName: Full=Mammalian target of rapamycin;
DE            Short=mTOR;
DE   AltName: Full=Mechanistic target of rapamycin;
DE   AltName: Full=Rapamycin target protein 1;
DE            Short=RAPT1;
GN   Name=Mtor {ECO:0000312|RGD:68371}; Synonyms=Frap1, Raft1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7822316; DOI=10.1074/jbc.270.2.815;
RA   Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J.,
RA   Wiederrecht G., Abraham R.T.;
RT   "Isolation of a protein target of the FKBP12-rapamycin complex in mammalian
RT   cells.";
RL   J. Biol. Chem. 270:815-822(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7518356; DOI=10.1016/0092-8674(94)90570-3;
RA   Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H.;
RT   "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent
RT   fashion and is homologous to yeast TORs.";
RL   Cell 78:35-43(1994).
RN   [3]
RP   PROTEIN SEQUENCE OF 215-226 AND 533-541, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U., Lubec S.;
RL   Submitted (SEP-2007) to UniProtKB.
RN   [4]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND EIF4EBP1, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=9465032; DOI=10.1073/pnas.95.4.1432;
RA   Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M.;
RT   "RAFT1 phosphorylation of the translational regulators p70 S6 kinase and
RT   4E-BP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:1432-1437(1998).
RN   [5]
RP   PHOSPHORYLATION AT THR-2164.
RX   PubMed=21576368; DOI=10.1128/mcb.05437-11;
RA   Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P.,
RA   Fingar D.C.;
RT   "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth,
RT   and cell cycle progression.";
RL   Mol. Cell. Biol. 31:2787-2801(2011).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [7]
RP   PHOSPHORYLATION AT SER-2448.
RX   PubMed=24187137; DOI=10.1074/jbc.m113.500736;
RA   Seldin M.M., Lei X., Tan S.Y., Stanson K.P., Wei Z., Wong G.W.;
RT   "Skeletal muscle-derived myonectin activates the mammalian target of
RT   rapamycin (mTOR) pathway to suppress autophagy in liver.";
RL   J. Biol. Chem. 288:36073-36082(2013).
CC   -!- FUNCTION: Serine/threonine protein kinase which is a central regulator
CC       of cellular metabolism, growth and survival in response to hormones,
CC       growth factors, nutrients, energy and stress signals (By similarity).
CC       MTOR directly or indirectly regulates the phosphorylation of at least
CC       800 proteins (By similarity). Functions as part of 2 structurally and
CC       functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR
CC       complex 1 and 2) (By similarity). In response to nutrients, growth
CC       factors or amino acids, mTORC1 is recruited to the lysosome membrane
CC       and promotes protein, lipid and nucleotide synthesis by phosphorylating
CC       key regulators of mRNA translation and ribosome synthesis (By
CC       similarity). This includes phosphorylation of EIF4EBP1 and release of
CC       its inhibition toward the elongation initiation factor 4E (eiF4E) (By
CC       similarity). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2
CC       that promote protein synthesis by modulating the activity of their
CC       downstream targets including ribosomal protein S6, eukaryotic
CC       translation initiation factor EIF4B, and the inhibitor of translation
CC       initiation PDCD4 (PubMed:9465032). Stimulates the pyrimidine
CC       biosynthesis pathway, both by acute regulation through RPS6KB1-mediated
CC       phosphorylation of the biosynthetic enzyme CAD, and delayed regulation,
CC       through transcriptional enhancement of the pentose phosphate pathway
CC       which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric
CC       activator of CAD at a later step in synthesis, this function is
CC       dependent on the mTORC1 complex (By similarity). Regulates ribosome
CC       synthesis by activating RNA polymerase III-dependent transcription
CC       through phosphorylation and inhibition of MAF1 an RNA polymerase III-
CC       repressor (By similarity). Activates dormant ribosomes by mediating
CC       phosphorylation of SERBP1, leading to SERBP1 inactivation and
CC       reactivation of translation (By similarity). In parallel to protein
CC       synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and
CC       LPIN1 (By similarity). To maintain energy homeostasis mTORC1 may also
CC       regulate mitochondrial biogenesis through regulation of PPARGC1A (By
CC       similarity). In the same time, mTORC1 inhibits catabolic pathways:
CC       negatively regulates autophagy through phosphorylation of ULK1 (By
CC       similarity). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-
CC       758', disrupting the interaction with AMPK and preventing activation of
CC       ULK1 (By similarity). Also prevents autophagy through phosphorylation
CC       of the autophagy inhibitor DAP (By similarity). Also prevents autophagy
CC       by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (By
CC       similarity). Prevents autophagy by mediating phosphorylation of AMBRA1,
CC       thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and
CC       interaction between AMBRA1 and PPP2CA (By similarity). mTORC1 exerts a
CC       feedback control on upstream growth factor signaling that includes
CC       phosphorylation and activation of GRB10 a INSR-dependent signaling
CC       suppressor (By similarity). Among other potential targets mTORC1 may
CC       phosphorylate CLIP1 and regulate microtubules (By similarity). The
CC       mTORC1 complex is inhibited in response to starvation and amino acid
CC       depletion (By similarity). The non-canonical mTORC1 complex, which acts
CC       independently of RHEB, specifically mediates phosphorylation of MiT/TFE
CC       factors TFEB and TFE3 in the presence of nutrients, promoting their
CC       cytosolic retention and inactivation (By similarity). Upon starvation
CC       or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and
CC       nuclear translocation of TFEB and TFE3, promoting their transcription
CC       factor activity (By similarity). The mTORC1 complex regulates
CC       pyroptosis in macrophages by promoting GSDMD oligomerization (By
CC       similarity). MTOR phosphorylates RPTOR which in turn inhibits mTORC1
CC       (By similarity). As part of the mTORC2 complex MTOR may regulate other
CC       cellular processes including survival and organization of the
CC       cytoskeleton (By similarity). mTORC2 plays a critical role in the
CC       phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of
CC       phosphoinositide 3-kinase, facilitating its activation by PDK1 (By
CC       similarity). mTORC2 may regulate the actin cytoskeleton, through
CC       phosphorylation of PRKCA, PXN and activation of the Rho-type guanine
CC       nucleotide exchange factors RHOA and RAC1A or RAC1B (By similarity).
CC       mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (By
CC       similarity). Regulates osteoclastogenesis by adjusting the expression
CC       of CEBPB isoforms (By similarity). Plays an important regulatory role
CC       in the circadian clock function; regulates period length and rhythm
CC       amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By
CC       similarity). {ECO:0000250|UniProtKB:P42345,
CC       ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:9465032}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:9465032};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:9465032};
CC   -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to
CC       nutrients, growth factors or amino acids: activation requires
CC       relocalization of the mTORC1 complex to lysosomes that is mediated by
CC       the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA,
CC       RagB/RRAGB, RagC/RRAGC and RagD/RRAGD. Activation of mTORC1 by growth
CC       factors such as insulin involves AKT1-mediated phosphorylation of TSC1-
CC       TSC2, which leads to the activation of the RHEB GTPase a potent
CC       activator of the protein kinase activity of mTORC1. Insulin-stimulated
CC       and amino acid-dependent phosphorylation at Ser-1261 promotes
CC       autophosphorylation and the activation of mTORC1. On the other hand,
CC       low cellular energy levels can inhibit mTORC1 through activation of
CC       PRKAA1 while hypoxia inhibits mTORC1 through a REDD1-dependent
CC       mechanism which may also require PRKAA1. The kinase activity of MTOR
CC       within the mTORC1 complex is positively regulated by MLST8. The kinase
CC       activity of MTOR is inhibited by DEPTOR and AKT1S1. The non-canonical
CC       mTORC1 complex is independent of the RHEB GTPase and specifically
CC       mediates phosphorylation of MiT/TFE factors TFEB and TFE3 but not other
CC       mTORC1 substrates: it is activated by FLCN, which activates Rag GTPases
CC       RagC/RRAGC and RagD/RRAGD. MTOR is the target of the immunosuppressive
CC       and anti-cancer drug rapamycin which acts in complex with
CC       FKBP1A/FKBP12, and specifically inhibits its kinase activity. mTORC2 is
CC       also activated by growth factors, but seems to be nutrient-insensitive.
CC       mTORC2 may also be regulated by RHEB but in an indirect manner through
CC       the PI3K signaling pathway. {ECO:0000250|UniProtKB:P42345}.
CC   -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1)
CC       which contains MTOR, MLST8 and RPTOR. The mTORC1 complex is a 1 Md
CC       obligate dimer of two stoichiometric heterotetramers with overall
CC       dimensions of 290 A x 210 A x 135 A. It has a rhomboid shape and a
CC       central cavity, the dimeric interfaces are formed by interlocking
CC       interactions between the two MTOR and the two RPTOR subunits. The MLST8
CC       subunit forms distal foot-like protuberances, and contacts only one
CC       MTOR within the complex, while the small AKT1S1/PRAS40 localizes to the
CC       midsection of the central core, in close proximity to RPTOR. mTORC1
CC       associates with AKT1S1/PRAS40, which inhibits its activity by blocking
CC       MTOR substrate-recruitment site. Part of the mechanistic target of
CC       rapamycin complex 2 (mTORC2) which contains MTOR, MLST8, PRR5, RICTOR,
CC       MAPKAP1 and DEPTOR (By similarity). Interacts with PLPP7 and PML (By
CC       similarity). Interacts with PRR5 and RICTOR; the interaction is direct
CC       within the mTORC2 complex and interaction with RICTOR is enhanced by
CC       deubiquitination of RICTOR by USP9X. mTORC1 and mTORC2 associate with
CC       DEPTOR, which regulates its activity. Interacts with WAC; WAC
CC       positively regulates MTOR activity by promoting the assembly of the TTT
CC       complex composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed
CC       of RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the
CC       dimerization of the mTORC1 complex and its subsequent activation.
CC       Interacts with UBQLN1. Interacts with TTI1 and TELO2. Interacts with
CC       CLIP1; phosphorylates and regulates CLIP1. Interacts with NBN.
CC       Interacts with HTR6. Interacts with BRAT1. Interacts with MEAK7 (via C-
CC       terminal domain); the interaction increases upon nutrient stimulation.
CC       Interacts with TM4SF5; the interaction is positively regulated by
CC       arginine and is negatively regulated by leucine. Interacts with
CC       GPR137B. Interacts with NCKAP1L. Interacts with TPCN1 and TPCN2; the
CC       interaction is required for TPCN1 and TPCN2 sensitivity to ATP (By
CC       similarity). Interacts with ATP6V1A and with CRYAB, forming a ternary
CC       complex (By similarity). Interacts with SLC38A7; this interaction
CC       mediates the recruitment of mTORC1 to the lysosome and its subsequent
CC       activation (By similarity). Interacts with TSPAN8 (By similarity).
CC       {ECO:0000250|UniProtKB:P42345, ECO:0000250|UniProtKB:Q9JLN9}.
CC   -!- INTERACTION:
CC       P42346; Q8TB45: DEPTOR; Xeno; NbExp=2; IntAct=EBI-1571489, EBI-2359040;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000250|UniProtKB:P42345};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:P42345}; Cytoplasmic
CC       side {ECO:0000250|UniProtKB:P42345}. Endoplasmic reticulum membrane
CC       {ECO:0000250|UniProtKB:P42345}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P42345}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:P42345}. Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:P42345}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P42345}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:P42345}. Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:P42345}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P42345}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:P42345}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P42345}. Nucleus {ECO:0000250|UniProtKB:Q9JLN9}.
CC       Nucleus, PML body {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane
CC       {ECO:0000250|UniProtKB:P42345}. Cytoplasmic vesicle, phagosome
CC       {ECO:0000250|UniProtKB:P42345}. Note=Shuttles between cytoplasm and
CC       nucleus. Accumulates in the nucleus in response to hypoxia (By
CC       similarity). Targeting to lysosomes depends on amino acid availability
CC       and RRAGA and RRAGB. Lysosome targeting also depends on interaction
CC       with MEAK7. Translocates to the lysosome membrane in the presence of
CC       TM4SF5 (By similarity). {ECO:0000250|UniProtKB:P42345,
CC       ECO:0000250|UniProtKB:Q9JLN9}.
CC   -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a
CC       highly restricted catalytic center. {ECO:0000250|UniProtKB:P42345}.
CC   -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha-
CC       helical TPR repeats plus a single subdomain of HEAT repeats. The four
CC       domains pack sequentially to form a C-shaped a-solenoid that clamps
CC       onto the kinase domain (By similarity). {ECO:0000250|UniProtKB:P42345}.
CC   -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (By similarity).
CC       Phosphorylation at Ser-1261, Ser-2159 and Thr-2164 promotes
CC       autophosphorylation (By similarity). Phosphorylation in the kinase
CC       domain modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40
CC       and leads to increased intrinsic mTORC1 kinase activity (By
CC       similarity). Phosphorylation at Ser-2159 by TBK1 in response to growth
CC       factors and pathogen recognition receptors promotes mTORC1 activity (By
CC       similarity). Phosphorylation at Thr-2173 in the ATP-binding region by
CC       AKT1 strongly reduces kinase activity (By similarity).
CC       {ECO:0000250|UniProtKB:P42345}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L37085; AAA65929.1; -; mRNA.
DR   EMBL; U11681; AAA20091.1; -; mRNA.
DR   PIR; A54837; A54837.
DR   RefSeq; NP_063971.1; NM_019906.1.
DR   AlphaFoldDB; P42346; -.
DR   BMRB; P42346; -.
DR   SMR; P42346; -.
DR   BioGRID; 248568; 6.
DR   DIP; DIP-261N; -.
DR   IntAct; P42346; 10.
DR   MINT; P42346; -.
DR   STRING; 10116.ENSRNOP00000014167; -.
DR   BindingDB; P42346; -.
DR   ChEMBL; CHEMBL1075134; -.
DR   CarbonylDB; P42346; -.
DR   iPTMnet; P42346; -.
DR   PhosphoSitePlus; P42346; -.
DR   jPOST; P42346; -.
DR   PaxDb; 10116-ENSRNOP00000014167; -.
DR   GeneID; 56718; -.
DR   KEGG; rno:56718; -.
DR   UCSC; RGD:68371; rat.
DR   AGR; RGD:68371; -.
DR   CTD; 2475; -.
DR   RGD; 68371; Mtor.
DR   VEuPathDB; HostDB:ENSRNOG00000009615; -.
DR   eggNOG; KOG0891; Eukaryota.
DR   HOGENOM; CLU_000178_7_1_1; -.
DR   InParanoid; P42346; -.
DR   OrthoDB; 8448at2759; -.
DR   PhylomeDB; P42346; -.
DR   TreeFam; TF105134; -.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1632852; Macroautophagy.
DR   Reactome; R-RNO-165159; MTOR signalling.
DR   Reactome; R-RNO-166208; mTORC1-mediated signalling.
DR   Reactome; R-RNO-3371571; HSF1-dependent transactivation.
DR   Reactome; R-RNO-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-RNO-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-RNO-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-RNO-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-RNO-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-RNO-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-RNO-9639288; Amino acids regulate mTORC1.
DR   PRO; PR:P42346; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000009615; Expressed in skeletal muscle tissue and 18 other cell types or tissues.
DR   ExpressionAtlas; P42346; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0012505; C:endomembrane system; ISO:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005635; C:nuclear envelope; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0045335; C:phagocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; ISO:RGD.
DR   GO; GO:0099524; C:postsynaptic cytosol; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0031931; C:TORC1 complex; IDA:RGD.
DR   GO; GO:0031932; C:TORC2 complex; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051219; F:phosphoprotein binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0043022; F:ribosome binding; ISO:RGD.
DR   GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; ISO:RGD.
DR   GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; ISO:RGD.
DR   GO; GO:0048266; P:behavioral response to pain; ISO:RGD.
DR   GO; GO:0033173; P:calcineurin-NFAT signaling cascade; ISO:RGD.
DR   GO; GO:0055006; P:cardiac cell development; ISO:RGD.
DR   GO; GO:0055013; P:cardiac muscle cell development; ISO:RGD.
DR   GO; GO:0060048; P:cardiac muscle contraction; ISO:RGD.
DR   GO; GO:0048738; P:cardiac muscle tissue development; ISO:RGD.
DR   GO; GO:0030030; P:cell projection organization; IGI:MGI.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; ISS:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; ISO:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:RGD.
DR   GO; GO:0071233; P:cellular response to L-leucine; ISO:RGD.
DR   GO; GO:1990253; P:cellular response to leucine starvation; ISO:RGD.
DR   GO; GO:0061431; P:cellular response to methionine; ISO:RGD.
DR   GO; GO:0031670; P:cellular response to nutrient; ISO:RGD.
DR   GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:UniProtKB.
DR   GO; GO:0006112; P:energy reserve metabolic process; ISO:RGD.
DR   GO; GO:0007281; P:germ cell development; ISO:RGD.
DR   GO; GO:0003007; P:heart morphogenesis; ISO:RGD.
DR   GO; GO:0003179; P:heart valve morphogenesis; ISO:RGD.
DR   GO; GO:0006954; P:inflammatory response; ISO:RGD.
DR   GO; GO:0007616; P:long-term memory; IMP:RGD.
DR   GO; GO:0007040; P:lysosome organization; ISS:UniProtKB.
DR   GO; GO:0016236; P:macroautophagy; ISO:RGD.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IDA:RGD.
DR   GO; GO:0048255; P:mRNA stabilization; IMP:RGD.
DR   GO; GO:0035264; P:multicellular organism growth; ISO:RGD.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:RGD.
DR   GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; ISO:RGD.
DR   GO; GO:0045792; P:negative regulation of cell size; IMP:MGI.
DR   GO; GO:1904193; P:negative regulation of cholangiocyte apoptotic process; IMP:RGD.
DR   GO; GO:1904213; P:negative regulation of iodide transmembrane transport; IMP:RGD.
DR   GO; GO:1905672; P:negative regulation of lysosome organization; ISS:UniProtKB.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; ISO:RGD.
DR   GO; GO:0014736; P:negative regulation of muscle atrophy; IMP:RGD.
DR   GO; GO:1900181; P:negative regulation of protein localization to nucleus; ISS:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IMP:RGD.
DR   GO; GO:0019228; P:neuronal action potential; ISO:RGD.
DR   GO; GO:0051647; P:nucleus localization; ISS:UniProtKB.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; ISO:RGD.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; ISO:RGD.
DR   GO; GO:0061051; P:positive regulation of cell growth involved in cardiac muscle cell development; IMP:RGD.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; IMP:RGD.
DR   GO; GO:1904056; P:positive regulation of cholangiocyte proliferation; IMP:RGD.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IMP:RGD.
DR   GO; GO:1904000; P:positive regulation of eating behavior; IMP:RGD.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:RGD.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IMP:RGD.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:RGD.
DR   GO; GO:1904197; P:positive regulation of granulosa cell proliferation; IMP:RGD.
DR   GO; GO:0051549; P:positive regulation of keratinocyte migration; ISO:RGD.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISO:RGD.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0010831; P:positive regulation of myotube differentiation; ISO:RGD.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; IMP:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:0014042; P:positive regulation of neuron maturation; IMP:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:RGD.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IMP:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:1904206; P:positive regulation of skeletal muscle hypertrophy; IMP:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISO:RGD.
DR   GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; ISO:RGD.
DR   GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; ISO:RGD.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:RGD.
DR   GO; GO:0045948; P:positive regulation of translational initiation; ISO:RGD.
DR   GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; ISO:RGD.
DR   GO; GO:0009791; P:post-embryonic development; ISO:RGD.
DR   GO; GO:0031648; P:protein destabilization; ISS:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISO:RGD.
DR   GO; GO:2000785; P:regulation of autophagosome assembly; ISO:RGD.
DR   GO; GO:0010506; P:regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0090335; P:regulation of brown fat cell differentiation; IMP:RGD.
DR   GO; GO:0006109; P:regulation of carbohydrate metabolic process; IDA:RGD.
DR   GO; GO:0043610; P:regulation of carbohydrate utilization; IDA:RGD.
DR   GO; GO:0001558; P:regulation of cell growth; ISO:RGD.
DR   GO; GO:0008361; P:regulation of cell size; ISO:RGD.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0031998; P:regulation of fatty acid beta-oxidation; IDA:RGD.
DR   GO; GO:0005979; P:regulation of glycogen biosynthetic process; IDA:RGD.
DR   GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB.
DR   GO; GO:0090559; P:regulation of membrane permeability; ISO:RGD.
DR   GO; GO:0031641; P:regulation of myelination; ISO:RGD.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0032095; P:regulation of response to food; IDA:RGD.
DR   GO; GO:0099547; P:regulation of translation at synapse, modulating synaptic transmission; IDA:SynGO.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:0043200; P:response to amino acid; ISO:RGD.
DR   GO; GO:0042220; P:response to cocaine; IMP:RGD.
DR   GO; GO:0009408; P:response to heat; ISO:RGD.
DR   GO; GO:0032868; P:response to insulin; ISO:RGD.
DR   GO; GO:0007584; P:response to nutrient; ISO:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0031529; P:ruffle organization; ISO:RGD.
DR   GO; GO:0035176; P:social behavior; IMP:RGD.
DR   GO; GO:0021510; P:spinal cord development; IDA:RGD.
DR   GO; GO:0002296; P:T-helper 1 cell lineage commitment; ISO:RGD.
DR   GO; GO:0031929; P:TOR signaling; ISS:UniProtKB.
DR   GO; GO:0038202; P:TORC1 signaling; ISS:UniProtKB.
DR   GO; GO:0008542; P:visual learning; IMP:RGD.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; ISO:RGD.
DR   CDD; cd05169; PIKKc_TOR; 1.
DR   Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1.
DR   Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR050517; DDR_Repair_Kinase.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR009076; FRB_dom.
DR   InterPro; IPR036738; FRB_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024585; mTOR_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR026683; TOR_cat.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1.
DR   PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF08771; FRB_dom; 1.
DR   Pfam; PF11865; mTOR_dom; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM01346; DUF3385; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SMART; SM01345; Rapamycin_bind; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Biological rhythms; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Endoplasmic reticulum;
KW   Golgi apparatus; Kinase; Lysosome; Magnesium; Membrane; Metal-binding;
KW   Microsome; Mitochondrion; Mitochondrion outer membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; TPR repeat; Transferase.
FT   CHAIN           1..2549
FT                   /note="Serine/threonine-protein kinase mTOR"
FT                   /id="PRO_0000088810"
FT   REPEAT          16..53
FT                   /note="HEAT 1"
FT   REPEAT          55..99
FT                   /note="HEAT 2"
FT   REPEAT          100..137
FT                   /note="HEAT 3"
FT   REPEAT          138..179
FT                   /note="HEAT 4"
FT   REPEAT          180..220
FT                   /note="HEAT 5"
FT   REPEAT          222..276
FT                   /note="HEAT 6"
FT   REPEAT          277..313
FT                   /note="HEAT 7"
FT   REPEAT          314..364
FT                   /note="HEAT 8"
FT   REPEAT          365..409
FT                   /note="HEAT 9"
FT   REPEAT          410..445
FT                   /note="HEAT 10"
FT   REPEAT          446..494
FT                   /note="HEAT 11"
FT   REPEAT          495..529
FT                   /note="HEAT 12"
FT   REPEAT          530..563
FT                   /note="HEAT 13"
FT   REPEAT          564..596
FT                   /note="HEAT 14"
FT   REPEAT          597..636
FT                   /note="HEAT 15"
FT   REPEAT          637..683
FT                   /note="HEAT 16"
FT   REPEAT          686..724
FT                   /note="HEAT 17"
FT   REPEAT          727..766
FT                   /note="HEAT 18"
FT   REPEAT          769..811
FT                   /note="HEAT 19"
FT   REPEAT          814..853
FT                   /note="HEAT 20"
FT   REPEAT          857..893
FT                   /note="HEAT 21"
FT   REPEAT          894..942
FT                   /note="HEAT 22"
FT   REPEAT          943..988
FT                   /note="HEAT 23"
FT   REPEAT          989..1027
FT                   /note="HEAT 24"
FT   REPEAT          1029..1068
FT                   /note="HEAT 25"
FT   REPEAT          1069..1105
FT                   /note="HEAT 26"
FT   REPEAT          1106..1144
FT                   /note="HEAT 27"
FT   REPEAT          1145..1188
FT                   /note="HEAT 28"
FT   REPEAT          1189..1225
FT                   /note="HEAT 29"
FT   REPEAT          1226..1273
FT                   /note="HEAT 30"
FT   REPEAT          1274..1311
FT                   /note="HEAT 31"
FT   REPEAT          1312..1345
FT                   /note="HEAT 32"
FT   REPEAT          1346..1382
FT                   /note="TPR 1"
FT   DOMAIN          1382..1982
FT                   /note="FAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534"
FT   REPEAT          1383..1408
FT                   /note="TPR 2"
FT   REPEAT          1409..1442
FT                   /note="TPR 3"
FT   REPEAT          1443..1473
FT                   /note="TPR 4"
FT   REPEAT          1474..1507
FT                   /note="TPR 5"
FT   REPEAT          1508..1541
FT                   /note="TPR 6"
FT   REPEAT          1542..1574
FT                   /note="TPR 7"
FT   REPEAT          1575..1614
FT                   /note="TPR 8"
FT   REPEAT          1615..1649
FT                   /note="TPR 9"
FT   REPEAT          1650..1693
FT                   /note="TPR 10"
FT   REPEAT          1694..1731
FT                   /note="TPR 11"
FT   REPEAT          1732..1786
FT                   /note="TPR 12"
FT   REPEAT          1787..1846
FT                   /note="TPR 13"
FT   REPEAT          1898..1930
FT                   /note="TPR 14"
FT   REPEAT          1931..1970
FT                   /note="TPR 15"
FT   REPEAT          1971..2005
FT                   /note="TPR 16"
FT   DOMAIN          2156..2469
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          2517..2549
FT                   /note="FATC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534,
FT                   ECO:0000255|PROSITE-ProRule:PRU00535"
FT   REGION          1..651
FT                   /note="Interaction with NBN"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   REGION          1812..1867
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2012..2144
FT                   /note="Sufficient for interaction with the FKBP1A/rapamycin
FT                   complex"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLN9"
FT   REGION          2162..2168
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2258..2296
FT                   /note="Interaction with MLST8"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   REGION          2335..2343
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          2355..2380
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   COMPBIAS        1822..1867
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         2165
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2167
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2185
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2187
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2190
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2225
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2238
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2239
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2240
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2245
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2343
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2345
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2356
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   BINDING         2357
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         567
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         1162
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         1218
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         1261
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         2159
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         2164
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:21576368"
FT   MOD_RES         2173
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         2446
FT                   /note="Phosphothreonine; by RPS6KB1"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         2448
FT                   /note="Phosphoserine; by RPS6KB1"
FT                   /evidence="ECO:0000269|PubMed:24187137"
FT   MOD_RES         2478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
FT   MOD_RES         2481
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P42345"
SQ   SEQUENCE   2549 AA;  288794 MW;  BE841EA7B9086F99 CRC64;
     MLGTGPATAT AGAATSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES
     TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN STRIGRFANY LRNLLPSSDP
     VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP
     TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE
     AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC
     KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGASPS PTKSTLVESR
     CCRDLMEEKF DQVCQWVLKC RSSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV
     LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKTVQVDA
     TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL
     KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVA SITLALRTLG SFEFEGHSLT
     QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL
     VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS
     MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI
     LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FVIIMDMLQD SSLLAKRQVA
     LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK
     VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR
     DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV
     SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR
     VFMHDNSQGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEVPLP SRKAALETVD
     RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV
     RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSS QGDALASGPV ETGPMKKLHV
     STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA
     AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI
     VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAS GVLEYAMKHF
     GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK
     WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA
     QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW
     ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD
     PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK
     QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA
     VLHYKHQNQA RDEKKKLRHA SGANITNATT TATTAASAAA ATSTEGSNSE SEAESNESSP
     TPSPLQKKVT EDLSKTLLLY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN
     EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS
     KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG
     ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA
     WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL
     QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL
     SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL
     MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH
     PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRTTC
     HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNAKGNK RSRTRTDSYS AGQSVEILDG
     VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD
     VPTQVELLIK QATSHENLCQ CYIGWCPFW
//
